Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase‐4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24‐week multicentre, randomized, double‐blind, placebo‐controlled phase III trial

We assessed the 24‐week efficacy and safety of teneligliptin, a novel dipeptidyl peptidase‐4 inhibitor, in Korean patients with type 2 diabetes mellitus (T2DM) that was inadequately controlled with diet and exercise. The present study was designed as a multicentre, randomized, double‐blind, placebo‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, S., Park, C.‐Y., Han, K. A., Chung, C. H., Ku, B. J., Jang, H. C., Ahn, C. W., Lee, M.‐K., Moon, M. K., Son, H. S., Lee, C. B., Cho, Y.‐W., Park, S.‐W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2016
Materias:
Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069603/
https://www.ncbi.nlm.nih.gov/pubmed/26749529
http://dx.doi.org/10.1111/dom.12631

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069603/
https://www.ncbi.nlm.nih.gov/pubmed/26749529
http://dx.doi.org/10.1111/dom.12631

Ejemplares similares